What is Hemolytic Anemia
Hemolytic anemia is a condition characterized by the premature destruction of red blood cells (RBCs), resulting in decreased circulating erythrocytes and a shortened RBC lifespan from the normal 120 days to significantly less. 1
Core Pathophysiology
The fundamental mechanism involves accelerated RBC destruction that exceeds the bone marrow's compensatory capacity to produce new cells. This destruction can occur through two primary pathways:
- Intravascular hemolysis: RBCs are destroyed directly within blood vessels
- Extravascular hemolysis: RBCs are trapped and destroyed in the reticuloendothelial system (primarily spleen and liver) 1
The destruction mechanisms include poor RBC deformability leading to trapping and phagocytosis, antibody-mediated destruction through phagocytosis or complement activation, fragmentation from microthrombi or mechanical trauma, oxidation, or direct cellular destruction 1.
Clinical Presentation
Patients typically present with:
- Acute anemia with fatigue and dyspnea
- Jaundice (from increased unconjugated bilirubin)
- Hematuria (in intravascular hemolysis)
- Tachycardia
- Possible hypotension in severe cases 1
Diagnostic Laboratory Findings
The pathognomonic laboratory pattern includes reticulocytosis (compensatory bone marrow response), elevated lactate dehydrogenase (LDH), elevated unconjugated bilirubin, and decreased haptoglobin levels 2, 1. The direct antiglobulin test (DAT) differentiates immune from non-immune causes 3, 1.
Additional key findings:
- Peripheral blood smear showing abnormal RBC morphologies (schistocytes >1% support diagnosis, though absence doesn't exclude it) 3
- Negative direct Coombs test in non-immune hemolysis 3
- Normocytic or macrocytic anemia pattern 1
Classification Systems
Hemolytic anemias are categorized into:
Hereditary Forms
- Membranopathies: Hereditary spherocytosis (characterized by spherocytes, family history, negative DAT) 4
- Enzymopathies: G6PD deficiency (hemolysis triggered by oxidative stress) 4
- Hemoglobinopathies: Sickle cell disease, thalassemias 4
Acquired Forms
- Autoimmune: Warm AIHA (IgG-mediated, 60-70% of cases), Cold agglutinin disease (IgM-mediated, 20-25%), mixed forms 5, 6
- Microangiopathic: Thrombotic microangiopathies including atypical HUS 3
- Infectious: Malaria, babesiosis 4
- Drug-induced: Through various mechanisms 1, 6
- Secondary: Associated with malignancies, autoimmune disorders, transfusion reactions 4
Critical Diagnostic Pitfall
When anemia plus thrombocytopenia presents in emergency settings, immediately measure haptoglobin, indirect bilirubin, and LDH levels 3. This triad of non-immune hemolytic anemia, thrombocytopenia, and renal involvement requires urgent differentiation between secondary HUS, aHUS, and TTP by determining ADAMTS13 activity (<10 IU/dL indicates TTP) 3.
Genetic Testing Considerations
When conventional laboratory tests fail to identify the cause, next-generation sequencing has demonstrated a 62% diagnostic yield in pediatric hereditary hemolytic anemia 7. Sanger sequencing combined with conventional testing remains efficient for thalassemias and hemoglobinopathies, though NGS-based screening is increasingly preferred for heterogeneous disorders 2, 7.